These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

132 related articles for article (PubMed ID: 8251476)

  • 21. Ras farnesyltransferase: a new therapeutic target.
    Leonard DM
    J Med Chem; 1997 Sep; 40(19):2971-90. PubMed ID: 9301658
    [No Abstract]   [Full Text] [Related]  

  • 22. High level expression of mammalian protein farnesyltransferase in a baculovirus system. The purified protein contains zinc.
    Chen WJ; Moomaw JF; Overton L; Kost TA; Casey PJ
    J Biol Chem; 1993 May; 268(13):9675-80. PubMed ID: 8486655
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Sequence requirement for peptide recognition by rat brain p21ras protein farnesyltransferase.
    Reiss Y; Stradley SJ; Gierasch LM; Brown MS; Goldstein JL
    Proc Natl Acad Sci U S A; 1991 Feb; 88(3):732-6. PubMed ID: 1992464
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Benzodiazepine peptidomimetic inhibitors of farnesyltransferase.
    Marsters JC; McDowell RS; Reynolds ME; Oare DA; Somers TC; Stanley MS; Rawson TE; Struble ME; Burdick DJ; Chan KS
    Bioorg Med Chem; 1994 Sep; 2(9):949-57. PubMed ID: 7712130
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Crystal structure of protein farnesyltransferase at 2.25 angstrom resolution.
    Park HW; Boduluri SR; Moomaw JF; Casey PJ; Beese LS
    Science; 1997 Mar; 275(5307):1800-4. PubMed ID: 9065406
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Design and synthesis of non-peptide Ras CAAX mimetics as potent farnesyltransferase inhibitors.
    Qian Y; Vogt A; Sebti SM; Hamilton AD
    J Med Chem; 1996 Jan; 39(1):217-23. PubMed ID: 8568811
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Bisubstrate inhibitors of farnesyltransferase: a novel class of specific inhibitors of ras transformed cells.
    Manne V; Yan N; Carboni JM; Tuomari AV; Ricca CS; Brown JG; Andahazy ML; Schmidt RJ; Patel D; Zahler R
    Oncogene; 1995 May; 10(9):1763-79. PubMed ID: 7753553
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Effect of insulin on farnesyltransferase activity in 3T3-L1 adipocytes.
    Goalstone ML; Draznin B
    J Biol Chem; 1996 Nov; 271(44):27585-9. PubMed ID: 8910345
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Protection against malignant conversion in SENCAR mouse skin by all trans retinoic acid: inhibition of the ras p21-processing enzyme farnesyltransferase and Ha-ras p21 membrane localization.
    Agarwal R; Mohan RR; Ahmad N; Mukhtar H
    Mol Carcinog; 1996 Sep; 17(1):13-22. PubMed ID: 8876671
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Ras C-terminal processing enzymes--new drug targets?
    Gibbs JB
    Cell; 1991 Apr; 65(1):1-4. PubMed ID: 2013090
    [No Abstract]   [Full Text] [Related]  

  • 31. [Conformational aspects of biological activity of functional fragments of the p21ras oncoproteins. 4. Address fragments of the receptor oncoproteins].
    Mzareulov KD
    Bioorg Khim; 2003; 29(4):373-83. PubMed ID: 12947758
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Nonfarnesylated tetrapeptide inhibitors of protein farnesyltransferase.
    Goldstein JL; Brown MS; Stradley SJ; Reiss Y; Gierasch LM
    J Biol Chem; 1991 Aug; 266(24):15575-8. PubMed ID: 1874715
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Farnesyltransferase inhibitors: a new class of cancer chemotherapeutics.
    Koblan KS; Kohl NE; Omer CA; Anthony NJ; Conner MW; deSolms SJ; Williams TM; Graham SL; Hartman GD; Oliff A; Gibbs JB
    Biochem Soc Trans; 1996 Aug; 24(3):688-92. PubMed ID: 8878827
    [No Abstract]   [Full Text] [Related]  

  • 34. Protein farnesyltransferase.
    Park HW; Beese LS
    Curr Opin Struct Biol; 1997 Dec; 7(6):873-80. PubMed ID: 9434909
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Role of the carboxyterminal residue in peptide binding to protein farnesyltransferase and protein geranylgeranyltransferase.
    Roskoski R; Ritchie P
    Arch Biochem Biophys; 1998 Aug; 356(2):167-76. PubMed ID: 9705207
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Protein prenylation: key to ras function and cancer intervention?
    Khosravi-Far R; Cox AD; Kato K; Der CJ
    Cell Growth Differ; 1992 Jul; 3(7):461-9. PubMed ID: 1419908
    [No Abstract]   [Full Text] [Related]  

  • 37. Development of tripeptidyl farnesyltransferase inhibitors.
    Lee HY; Sohn JH; Kwon BM
    Bioorg Med Chem Lett; 2002 Jun; 12(12):1599-602. PubMed ID: 12039571
    [TBL] [Abstract][Full Text] [Related]  

  • 38. [Conformational aspects of biological activity of functional fragments of the p21ras oncoproteins. 3. Fragment 34-46 of the native oncoprotein and the decapeptide corresponding to its 35-44 sequence].
    Mzareulov KD
    Bioorg Khim; 2003; 29(4):361-72. PubMed ID: 12947757
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Protein farnesyltransferase and geranylgeranyltransferase share a common alpha subunit.
    Seabra MC; Reiss Y; Casey PJ; Brown MS; Goldstein JL
    Cell; 1991 May; 65(3):429-34. PubMed ID: 2018975
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Inhibition of protein farnesyltransferase: a possible mechanism of tumor prevention by dehydroepiandrosterone sulfate.
    Schulz S; Nyce JW
    Carcinogenesis; 1994 Nov; 15(11):2649-52. PubMed ID: 7955120
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.